NIKKEI 225
37,960.61 -499.47 (-1.30%) HANG SENG
17,201.27 +372.34 (+2.21%) CRUDE OIL
82.76 -0.05 (-0.06%) GOLD FUTURES
2,329.80 -8.60 (-0.37%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,723.43 -1,660.23 (-3.11%)
Aclaris Therapeutics, Inc. (0H8T.L)
- PR Newswire
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately. Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies. He succeeds interim CEO Abbie Celniker, Ph
- Simply Wall St.
Favourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired Stock
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
- Zacks
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
